https://allsci.com/news/m-a/merck-kgaa-bio-techne-acquisition-clears-final/ AllScien 2026-09-23T16:45:09.675287Z Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle https://allsci.com/news/clinical-trials/cbl-514-dercums-disease-caliways-beats-placebo-in/ AllScien 2026-09-23T16:29:55.609099Z Caliway reports positive Phase IIb data for CBL-514 in Dercum’s disease https://allsci.com/news/licensing-and-partnerships/nucleic-acid-delivery-lung-mirai-bio-and-astar/ AllScien 2026-09-23T15:56:53.224702Z Mirai Bio and A*STAR team up to improve lung delivery of nucleic acid therapies https://allsci.com/news/regulatory-designations-pathways/fda-fast-track-px578-polg-disease-designation/ AllScien 2026-09-23T15:43:08.941231Z Pretzel’s POLG activator gains FDA Fast Track ahead of Phase II POLG disease trial https://allsci.com/news/grants/adaptive-red-blood-cells-darpa-scarlet/ AllScien 2026-09-23T15:29:12.634893Z Scarlet Therapeutics leads USD 14m DARPA-backed UK smart red blood cell consortium https://allsci.com/news/business/ovarian-cancer-trial-funding-oncoinvent-raises/ AllScien 2026-09-23T15:20:56.539969Z Norway’s Oncoinvent raises USD 16.2m to fund radiopharmaceutical ovarian cancer trial https://allsci.com/news/clinical-trials/sefaxersen-iga-nephropathy-roches-meets-phase-iii/ AllScien 2026-09-23T14:59:59.747652Z Roche's sefaxersen meets Phase III primary endpoint in IgA nephropathy trial https://allsci.com/news/approvals/trixeo-triple-inhaler-approval-eu-approves/ AllScien 2026-09-23T14:50:37.620598Z EU approves AstraZeneca's Trixeo as first triple-combination inhaler for inadequately controlled asthma https://allsci.com/news/business/grunenthal-stivarga-acquisition-expands-into/ AllScien 2026-09-23T14:26:58.816793Z Grünenthal expands into oncology with EUR 375 million Stivarga acquisition from Bayer https://allsci.com/news/licensing-and-partnerships/mash-liver-testing-siemens-healthineers-and-novo/ AllScien 2026-09-23T14:20:49.628261Z Siemens Healthineers, Novo partner to expand non-invasive liver fibrosis testing in MASH https://allsci.com/news/systimmune-phase-iii-lung-cancer-trial-hits-usd/ AllScien 2026-09-23T13:28:45.248756Z SystImmune hits USD 250m milestone from BMS as iza-bren Phase III lung cancer trial advances https://allsci.com/news/clinical-trials/laromestrocel-hlhs-trial-longeverons-fails-to/ AllScien 2026-09-23T10:41:41.188727Z Longeveron starts strategic review after laromestrocel failure to improve heart function in HLHS infants https://allsci.com/news/licensing-and-partnerships/t-cell-engager-license-deal-henlius-licenses-two/ AllScien 2026-09-23T10:35:09.170048Z Henlius looks to US biotech for global TCE rights in Amberstone deal https://allsci.com/news/clinical-trials/petrelintide-phase-iii-obesity-zealand-pharma/ AllScien 2026-09-23T10:05:50.690084Z Zealand launches Phase III program for amylin analog petrelintide in overweight and obesity https://allsci.com/news/clinical-trials/ulefnersen-fus-als-trial-otsukas-becomes-first-to/ AllScien 2026-09-23T09:56:01.510124Z Otsuka's ulefnersen becomes first to hit primary endpoint in placebo-controlled FUS-ALS trial https://allsci.com/news/clinical-trials/inaxaplin-amkd-phase-iib-vertex-expands/ AllScien 2026-09-23T07:05:34.751757Z Vertex posts Phase II data extending inaxaplin's reach in AMKD patient populations https://allsci.com/news/regulatory-designations-pathways/qrx003-fast-track-fda-peeling-skin-syndrome/ AllScien 2026-09-23T06:50:14.098785Z Quoin advances QRX003 in peeling skin syndrome with second FDA Fast Track https://allsci.com/news/clinical-trials/barzolvolimab-chronic-urticaria-celldexs-beats/ AllScien 2026-09-23T06:43:47.532256Z Celldex’s barzolvolimab scores pivotal CSU wins after recent setbacks https://allsci.com/news/clinical-trials/vk2735-weight-loss-maintenance-vikings-maintains/ AllScien 2026-09-22T21:42:16.276576Z Viking reports positive monthly and every-other-week VK2735 maintenance data https://allsci.com/news/development/adg138-nmpa-clearance-adagene-receives-for/ AllScien 2026-09-22T16:48:25.380312Z Adagene advancing HER2 bispecific TCE into clinic in China https://allsci.com/news/ipo-public-listing/iambic-therapeutics-ipo-files-for-backed-by-usd/ AllScien 2026-09-22T16:43:05.663547Z Iambic files for IPO after string of Big Pharma AI partnerships https://allsci.com/news/licensing-and-partnerships/friedreich-ataxia-acquisition-lexeo-expands/ AllScien 2026-09-22T16:27:28.665107Z Lexeo expands Friedreich ataxia platform with USD 21.3m Mantle acquisition and CNS collaborations https://allsci.com/news/regulatory-policy/fda-nonclinical-testing-terminology-issues-direct/ AllScien 2026-09-22T16:15:23.534524Z FDA modernizes drug regulations to formalize support for NAMs https://allsci.com/news/licensing-and-partnerships/oncology-collaboration-deal-envisagenics-and/ AllScien 2026-09-22T14:42:05.371371Z Boehringer, Envisagenics ink up to USD 1b RNA splicing oncology collaboration https://allsci.com/news/amgen-announces-positive-topline-phase-3-results/ AllScien 2026-09-22T14:09:55.022752Z Amgen’s dazodalibep meets Phase III endpoint in systemic Sjögren’s disease https://allsci.com/news/licensing-and-partnerships/radioligand-therapy-licensing-novartis-secures/ AllScien 2026-09-22T14:05:42.550717Z Novartis adds China-origin RLT asset through BoomRay licensing deal https://allsci.com/news/research/parp-inhibitor-resistance-ovarian-cancer/ AllScien 2026-09-22T13:48:14.376994Z Mayo Clinic researchers identify BCL-XL inhibition strategy to reverse PARP inhibitor resistance in ovarian cancer https://allsci.com/news/approvals/susvimo-neovascular-macular-degeneration/ AllScien 2026-09-22T12:12:03.226983Z European Commission approves Roche's Susvimo for neovascular age-related macular degeneration. https://allsci.com/news/clinical-trials/enicepatide-type-2-diabetes-roches-cuts-hba1c-by/ AllScien 2026-09-22T11:22:26.767190Z Roche advances enicepatide toward Phase III after positive diabetes trial https://allsci.com/news/clinical-trials/cagrisema-tirzepatide-type-2-diabetes-novos-tops/ AllScien 2026-09-22T09:57:37.534256Z Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint https://allsci.com/news/research/anaplastic-thyroid-cancer-research-md-anderson/ AllScien 2026-09-22T09:43:09.705451Z MD Anderson secures USD 2.7m NCI grant for four-part anaplastic thyroid cancer program https://allsci.com/news/approvals/rinvoq-juvenile-idiopathic-arthritis-european/ AllScien 2026-09-22T09:35:15.186058Z AbbVie's Rinvoq picks up EU nod for polyarticular juvenile idiopathic arthritis in children https://allsci.com/news/grants/lca9-gene-therapy-opus-genetics-secures-1m-nih/ AllScien 2026-09-22T09:00:28.811090Z Opus Genetics secures NIH grant for LCA9 gene therapy IND-enabling studies